In this month's Connection newsletter:
- Explore resources for respiratory diseases for Healthy Lung Month in October
- Learn about the new mandatory MyInsights Program survey training
- Access the latest Resource Center files available on FormularyDecisions
- Preview and register for upcoming AMCP Pre-approval Information Exchange (PIE) Webinars
Healthy Lung Month
October is Healthy Lung Month. In 2017, 544.9 million people worldwide had a chronic respiratory disease, representing an increase of 39.8% compared with 1990.1 FormularyDecisions offers various resources for acute and chronic diseases to assist you in making informed healthcare decisions for your patient and members.
Cell & Gene Therapy Hub
Explore cell and gene therapies across multiple therapeutic areas, including pulmonology in the Cell & Gene Therapy Hub. |
Clinical Guideline Snapshots
Review Clinical Guideline Snapshots on respiratory syncytial virus, COVID-19, asthma, and community-acquired pneumonia. |
Drug Class Review
Create a custom Drug Class Review table with respiratory products on FormularyDecisions. |
You can also visit the following disease pages to link to associated product pages and access the latest articles pulled into the Metasearch Results from up to 19 different publications.
CF Source
Cystic Fibrosis (CF) is a progressive and multisystemic disease. In a patient with CF, cystic fibrosis transmembrane conductance regulator (CFTR) protein dysfunction causes lung disease that begins early and progresses throughout their lifetime. CFSourceHCP.com is an educational website developed by Vertex Pharmaceuticals Incorporated that contains information on the multisystemic effects of CF and helpful resources for those looking for information on CF progression.
© 2024 Vertex Pharmaceuticals Incorporated | VXR-US-02-2400455 (v1.0) | 09/2024
This announcement is an advertisement paid for by Vertex Pharmaceuticals Incorporated. FormularyDecisions is not providing a product recommendation. Readers should review all available materials related to the product and indication discussed herein before making any decision related to the purchase or use of the product. Any questions about such products must be directed to the biopharma company.
New mandatory MyInsights Survey Training
Explore the latest Resource Center files
Several biopharma companies recently posted new or updated content in their Resource Centers, including product briefs, clinical overviews, publications, posters, and more! Many of these resources contain consolidated, up-to-date product information that you can include in your upcoming product reviews. See below for Resource Center files posted in the last 3 months.
Click here to view a list of all products with Resource Center files.
FDA-approved product namea |
Resource Center document description(s) |
|
Randomized controlled trial and association of Freestyle Libre utilization and glycemic outcomes |
|
|
Trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor)12 |
Cost analysis study on simplifying treatment for cystic fibrosis |
Key: COVID-19 – coronavirus disease; FDA – Food and Drug Administration; ICER – Institute for Clinical and Economic Review
Pre-approval product nameb |
Resource Center document description(s) |
Key: PIE – pre-approval information exchange.
This announcement is an advertisement paid for by IntraBio Inc. FormularyDecisions is not providing a product recommendation. Readers should review all available materials related to the product and indication discussed herein before making any decision related to the purchase or use of the product. Any questions about such products must be directed to the biopharma company.
AMCP PIE Webinar Session:
Rethinking schizophrenia: Prioritizing cognitive symptoms in schizophrenia careb
Date: Monday, October 21, 2024
Time: 2:00-3:00pm ET
This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.
Click below for webinar details and to register:
Time: 2:00-3:00pm ET
This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.
This PIE webinar is sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. The content of the webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP or FormularyDecisions. FormularyDecisions is proud to partner with AMCP to enable information sharing between healthcare decision makers and biopharma companies.
Click below for webinar details and to register:
AMCP PIE Webinar Session:
Preapproval information exchange in radicular leg pain associated with lumbar disc herniationb
Date: Thursday, October 24, 2024
Time: 2:00-3:00pm ET
This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.
Click below for webinar details and to register:
Time: 2:00-3:00pm ET
This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.
This PIE webinar is sponsored by Ferring Pharmaceuticals Inc. The content of the webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP or FormularyDecisions. FormularyDecisions is proud to partner with AMCP to enable information sharing between healthcare decision makers and biopharma companies.
Click below for webinar details and to register:
AMCP PIE Webinar Session:
Vutrisiran Preapproval Information Exchange Webinarb
Date: Wednesday, October 30, 2024
Time: 2:00-3:00pm ET
This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.
Click below for webinar details and to register:
Time: 2:00-3:00pm ET
This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.
This PIE webinar is sponsored by Alnylam Pharmaceuticals, Inc. The content of the webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP or FormularyDecisions. FormularyDecisions is proud to partner with AMCP to enable information sharing between healthcare decision makers and biopharma companies.
Click below for webinar details and to register:
References:
1. GBD Chronic Respiratory Disease Collaborators, et al. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020;8(6):585-596. https://doi.org/10.1016/S2213-2600(20)30105-3
2. Apretude prescribing information. ViiV Healthcare; 2024. https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Apretude/pdf/APRETUDE-PI-PIL-IFU.PDF
3. Cabenuva prescribing information. ViiV Healthcare; 2024. https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Cabenuva/pdf/CABENUVA-PI-PIL-IFU2-IFU3.PDF
4. Darzalex prescribing information. Janssen Biotech, Inc.; 2024. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf
5. Freestyle Libre 2. Abbott; 2024.
6. Imbruvica prescribing information. AbbVie Inc.; 2024. https://www.rxabbvie.com/pdf/imbruvica_pi.pdf
7. Joenja prescribing information. Pharming Healthcare Inc.; 2023. https://joenja.com/prescribing-information.pdf
8. Kerendia prescribing information. Bayer HealthCare Pharmaceuticals Inc.; 2022. https://labeling.bayerhealthcare.com/html/products/pi/Kerendia_PI.pdf
9. mRESVIA prescribing information. Moderna US, Inc; 2024. https://static.modernatx.com/pm/6cef78f8-8dad-4fc9-83d5-d2fbb7cff867/36130c97-6fb0-4bea-9f2e-fb5be7a90729/36130c97-6fb0-4bea-9f2e-fb5be7a90729_viewable_rendition__v.pdf
10. Nexlizet prescribing information. Esperion Therapeutics, Inc.; 2024. https://pi.esperion.com/nexlizet/nexlizet-pi.pdf
11. Saphnelo prescribing information. AstraZeneca Pharmaceuticals LP; 2024. https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/44b6985c-8268-46b1-ba3e-2bb43bfd4d4c/44b6985c-8268-46b1-ba3e-2bb43bfd4d4c_viewable_rendition__v.pdf
12. Trikafta prescribing information. Vertex Pharmaceuticals Incorporated; 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212273s009lbl.pdf
13. Voranigo prescribing information. Servier Pharmaceuticals LLC; 2024. https://d11vmvycldsjdg.cloudfront.net/7fffe4c3-9746-4e82-9582-df9879a712d5/5939acdd-1c44-41f5-b2f6-260ab3860288/5939acdd-1c44-41f5-b2f6-260ab3860288_web_ready__c.pdf
a The material is being shared to inform you of the availability of information on FormularyDecisions. In providing this information, FormularyDecisions is not promoting any products mentioned, making claims about risks or benefits, or otherwise recommending any product in general or for any patient or formulary. For complete information about the indications, risks, and benefits of any product, please consult appropriate clinical and safety information, including the complete product label and important safety information. All prescribing decisions and/or coverage decisions should be made independently by individuals with appropriate experience in reliance on their independent judgement.
b The products listed are in the clinical evaluation stage and have not been approved for use by the FDA. The safety and efficacy of these products have not been established. FormularyDecisions is providing this information to alert you to the status of this product and is not promoting this product generally or otherwise recommending this product for use in the treatment of any disease or inclusion on any formulary for which it has not yet been approved. Any questions about such products must be directed to the biopharma companies. The availability of this product information follows the guidance outlined in the Pre-approval Information Exchange Act of 2022 (Section 810 of H.R. 7667).
FormularyDecisions is owned and operated by Xcenda L.L.C., which is a subsidiary of Cencora, a global pharmaceutical sourcing and distribution services company.
The contents of this communication are non-promotional and intended exclusively for healthcare decision-makers, formulary committees, and other similar entities responsible for selecting healthcare products for coverage or reimbursement. Do not forward this communication. FormularyDecisions strongly encourages our members to review all available information about a particular product, including but not limited to the product label, and to rely on their experience and expertise in making decisions about coverage or prescribing.